Genomic Health Announces Presentation of Two Oncotype DX® Studies at the 2012 Breast Cancer Symposium
New findings reinforce value of Oncotype DX in node-positive breast cancer patients; separate presentation provides background on development of DCIS Score
SAN FRANCISCO, Sept. 13, 2012 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of distant recurrence, disease-free survival, and overall survival in women with node-positive breast cancer who were treated with anthracycline-containing chemotherapy regimens. Highlighted in the official meeting presscast, these study results will be presented during the 2012 Breast Cancer Symposium, September 13-15, in San Francisco.
"Personalized medicine requires an accurate assessment of the patient's individual tumor biology in order to help determine the most appropriate treatment plan," said Terry Mamounas, M.D., medical director, Aultman Cancer Center, and member of the National Surgical Adjuvant Breast and Bowel Project (NSABP) board. "These new data show that for lymph node-positive breast cancer patients, Oncotype DX can help identify those who will have excellent outcomes with adjuvant chemo-endocrine therapy, versus those who are at greater risk of recurrence and may need additional treatment."
This study analyzes tumor samples from 1,065 hormone-positive, node-positive breast cancer patients who were treated with anthracycline-containing chemotherapy as part of the NSABP B-28 trial. This evaluation of distant recurrence, disease-free survival, and overall survival, is part of a study that also includes analysis of B-28 data on local regional recurrence, to be reported at a later date.
"These results add to a large body of evidence, now totaling more than 2,000 patients, demonstrating that the Recurrence Score provides independent distant recurrence risk information that provides value beyond clinical and pathologic factors in node-positive disease," said Steven Shak, M.D., chief medical officer at Genomic Health. "Across multiple studies, we observe consistent support for the use of Oncotype DX as a useful tool to guide treatment decisions for early-stage breast cancer patients, including those with node-positive disease."
The oral presentation of the study, titled "Prognostic impact of the 21-gene Recurrence Score on disease-free and overall survival of node-positive, ER-positive breast cancer patients treated with adjuvant chemotherapy: Results from NSABP B-28" (Abstract #1), will take place on Thursday, September 13, 2012 at 9:30 a.m. Pacific Daylight Time.
Additionally, Genomic Health will present a poster on the development of the Oncotype DX DCIS Score™ that provides additional background information on the scaling and risk cut-off points based on a study of a broad population of 100 DCIS (ductal carcinoma in situ of the breast) patients. In this analysis, the DCIS Score was widely distributed over all clinical and pathologic characteristics assessed. The poster titled "The development of the DCIS score: Scaling and normalization in the Marin Medical Laboratories cohort" (Abstract #190), will be presented on Thursday, September 13, 2012, Poster Session A.
Six leading medical specialty societies co-sponsor the three-day, multidisciplinary symposium, including the American Society of Breast Disease, the American Society of Breast Surgeons, the American Society of Clinical Oncology, the American Society for Radiation Oncology, the National Consortium of Breast Centers and the Society of Surgical Oncology.